ArticleDiscover oncology2025
Identification and validation of prognostic markers for cuproptosis-related macrophage polarization genes in hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- scRNA-seq and bulk RNA-seq reveal the characteristics of macrophage copper metabolism and establish a risk signature in hepatocellular carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we used single-cell sequencing data analysis to explore differentially expressed genes in the polarization process of macrophages in hepatocellular carcinoma. We then integrated these genes with cuproptosis-related genes (CRGs) to identify potential biomarkers. Through a rigorous screening process, including univariate Cox regression analysis and machine learning algorithms, we identified six key risk genes: GLIPR2, ANP32E, LIPT1, ALAD, ARSK, and PGAM1. These genes form the foundation of our prognostic risk prediction model. ROC curve analysis showed that these models had high specificity and accuracy in predicting prognostic characteristics, and Kaplan-Meier curve analysis showed that the survival rate of the low-risk group was significantly higher than that of the high-risk group. In addition, patients stratified by our model showed differences in tumor microenvironment, sensitivity to immunotherapy, and response to chemotherapy. After incorporating patient clinical data, we constructed a nomogram that further improved the accuracy of predicting patient survival. We further analyzed the expression characteristics and spatial distribution of these six risk genes in hepatocellular carcinoma through bulk transcriptomics, single-cell, and spatial transcriptomics data, and validated the expression of risk genes using qPCR. The construction of predictive models in this study helps clinicians to predict the overall survival of patients with hepatocellular carcinoma, which enables patient stratification and has the potential to help personalize patient treatment. The discovery of candidate tumor markers helps to identify potential targeted therapeutic options, which will play a key role in the diagnosis and treatment of hepatocellular carcinoma in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.